Within this context and before the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor era, we initiated UNIRAD, a double-blind, multicenter, international randomized trial comparing the combination of adjuvant everolimus plus standard adjuvant ET versus placebo plus ET in patients with high-risk HR-positive/HER2-negative early breast cancer. Here, CDK4 is linked to breast carcinoma.